solid third quarter sustain growth across board
abbott post third-quart result report revenu billion roughli
million billion target compar oper basi revenu growth
constant-curr basi point better model growth
similar last quarter despit much tougher comp year date organ fxn foreign
exchang neutral revenu peer group
strength call clearli medic devic growth organ
fxn led diabet organ fxn electrophysiolog organ fxn
structur heart organ fxn rest busi larg line
expect realli noth call term laggard aler touch
light target noth worth get concern
took note manag commentari sustain top-lin result toward
higher end growth rate compani target heard clear
bullish manag indic growth strong mani year
come continu support reinvest effort compani made help drive
type result increas support new product increas sale
market drive uptak new product form bold acquisit
brought new product mix manag comment
return calcul invest would difficult believ
accret go remain place even expand come year
last point would expect invest continu grow compani
aggress pay debt see leverag come end
year leav manag flexibl go new busi noth
radar right though heard deal announc
shortli thereaft acceler addit capit flow new product develop
outsid divers growth perform busi quarter
surpris amount fx-relat commentari call understand fx
headwind unpredict quit understand fascin
topic given organ fxn earn growth doubl digit next year
even today rate fx impact would less hit growth believ
focu strong oper perform busi overal
anoth good quarter abbott reflect rare period time busi
essenti suppos appropri invest
made support futur opportun
abbott highli diversifi provid medic devic nutrit pharmaceut product
return equiti ttm
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
valuat stock thought
look forward pipelin new product launch gain traction acceler top-lin growth
synergi larg transact appear play least well expect combin believ
gener stabl strong perform variou organ busi abbott set top-tier revenu
earn growth ad on-going de-lever flexibl bring capit alloc discuss later
year along hundr million dollar increment sales-and-market spend thank upsid
perform lower tax rate durabl growth appear sound reason given still
quit reason valuat time ep estim fxn organ assum hit fx
continu recommend purchas stock
structur heart/mitraclip outlook structur heart busi bright fxn follow
strong result coapt present year tct meet septemb studi demonstr clinic
benefit mitral valv replac specif compani mitraclip procedur mitraclip approach
million sale year grow minim impact quarter coapt structur
heart busi fxn
remind coapt studi enrol patient moder sever mitral regurgit
primari endpoint hospit month patient random either guideline-
medic direct therapi gdmt gdmt plu mitraclip data unequivoc posit mitraclip show
significantli lower hospit rate compar gdmt-onli cohort lower all-
caus mortal vs gmdt cohort low device-rel complic rate
month
though compani need gain expand label pursu reimburs may see signific
inflect adopt believ clinician like increas use mitraclip next year
greater potenti inflect point second half million patient mitral
regurgit grade today patient treat mitraclip suggest
remain signific potenti demand market
diabet segment benefit strong global adopt freestyl libr support
underli year-over-year sale growth third quarter sale libr reach million third
quarter year-over-year libr million world-wide user
second quarter made intern patient notabl compani suggest
patient nearli doubl last day though still roughli type suggest product
larg expand market versu take share
abbott highlight robust demand libr system need continu invest
expans manufactur capabl sensor pipelin manag re-affirmed commit
launch libr provid expect might libr receiv ce mark earli
fourth quarter subsequ roll sever eu territori believ manag unchang
expect new patient revenu achiev segment remain one strongest
 diagnost organ fxn includ million rapid diagnost result essenti line
expect talk forward look get menu alin clinic chemistri immunoassay
analyz approxim menu item clear like need around
competit interestingli lab growth seen littl benefit alin
yet respect rapid diagnost aler manag turn refocus aler growth note
us come form exist product leverag better intern well
better maxim exist platform lastli manag note flu comp caus million
headwind wind see moder flu season alway suggest peopl assum
think unpredict respiratori season
updat model follow quarterli result manag guidanc
sale decreas sale estim billion oper constant currenc basi
previou estim billion manag guid oper constant-curr
earn maintain estim project modest uptick gross margin fourth
quarter compani benefit margin improv across busi
sale decreas sale estim billion compar previou estim
billion also
earn lower earn per share estim account larger
neg headwind foreign exchang head
